WO2004065392A8 - Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands - Google Patents

Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands

Info

Publication number
WO2004065392A8
WO2004065392A8 PCT/EP2004/000650 EP2004000650W WO2004065392A8 WO 2004065392 A8 WO2004065392 A8 WO 2004065392A8 EP 2004000650 W EP2004000650 W EP 2004000650W WO 2004065392 A8 WO2004065392 A8 WO 2004065392A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidines
alk
receptor ligands
therapy
condensed pyridines
Prior art date
Application number
PCT/EP2004/000650
Other languages
French (fr)
Other versions
WO2004065392A1 (en
Inventor
Nerina Dodic
Francoise Jeanne Gellibert
Robert Neil Hunter Iii
Original Assignee
Smithkline Beecham Corp
Nerina Dodic
Francoise Jeanne Gellibert
Robert Neil Hunter Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0301719A external-priority patent/GB0301719D0/en
Priority claimed from GB0308706A external-priority patent/GB0308706D0/en
Priority claimed from GB0315519A external-priority patent/GB0315519D0/en
Application filed by Smithkline Beecham Corp, Nerina Dodic, Francoise Jeanne Gellibert, Robert Neil Hunter Iii filed Critical Smithkline Beecham Corp
Publication of WO2004065392A1 publication Critical patent/WO2004065392A1/en
Publication of WO2004065392A8 publication Critical patent/WO2004065392A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Therapeutically active substituted quinoline and quinazoline compounds derivatives of formula (I) wherein X is N or CH, Y is NH, N (alkyl) or NH-CH2, and R2 and R3 are specified heterorings, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor β (TGF-β), and pharmaceutical compositions for use in such therapy are disclosed.
PCT/EP2004/000650 2003-01-24 2004-01-26 Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands WO2004065392A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0301719.1 2003-01-24
GB0301719A GB0301719D0 (en) 2003-01-24 2003-01-24 Compounds
GB0308706A GB0308706D0 (en) 2003-04-15 2003-04-15 Novel compounds
GB0308706.1 2003-04-15
GB0315519A GB0315519D0 (en) 2003-07-02 2003-07-02 Novel compounds
GB0315519.9 2003-07-02

Publications (2)

Publication Number Publication Date
WO2004065392A1 WO2004065392A1 (en) 2004-08-05
WO2004065392A8 true WO2004065392A8 (en) 2004-10-07

Family

ID=32776625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000650 WO2004065392A1 (en) 2003-01-24 2004-01-26 Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands

Country Status (1)

Country Link
WO (1) WO2004065392A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521398A (en) * 2003-03-28 2006-09-21 サイオス・インコーポレーテツド Bicyclic pyrimidine inhibitors of TGFβ
AU2004230928B2 (en) * 2003-04-09 2010-12-02 Exelixis, Inc. Tie-2 modulators and methods of use
GB0326963D0 (en) * 2003-11-19 2003-12-24 Glaxo Group Ltd Compounds
EP1799218A1 (en) * 2004-09-30 2007-06-27 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8252806B2 (en) * 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
CA2602294C (en) 2005-03-25 2015-02-24 Tibotec Pharmaceuticals Ltd. Heterobicylic inhibitors of hvc
AR056347A1 (en) 2005-05-12 2007-10-03 Tibotec Pharm Ltd USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS
WO2007011759A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
WO2007013964A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
CN101330914A (en) * 2005-12-16 2008-12-24 爱尔康公司 Control of intraocular pressure using ALK5 modulation agents
DE602006015861D1 (en) 2005-12-21 2010-09-09 Abbott Lab ANTIVIRAL CONNECTIONS
ES2395386T3 (en) 2005-12-21 2013-02-12 Abbott Laboratories Antiviral compounds
AU2006330924B2 (en) * 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
JP2009521460A (en) * 2005-12-21 2009-06-04 アボット・ラボラトリーズ Antiviral compounds
CA2652341A1 (en) * 2006-05-15 2007-11-22 Senex Biotechnology, Inc. Identification of cdki pathway inhibitors
AR061974A1 (en) 2006-07-14 2008-08-10 Novartis Ag PIRIMIDINE DERIVATIVES AS ALK INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND OBTAINING PROCESSES
EP1878733A1 (en) * 2006-07-14 2008-01-16 Novartis AG Pyrimidine derivatives as ALK-5 inhibitors
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
JP4937666B2 (en) * 2006-08-01 2012-05-23 東ソー株式会社 2-trifluoromethylquinolines and process for producing the same
TWI399380B (en) 2006-12-20 2013-06-21 Abbott Lab Anti-viral compounds
CA2676984C (en) * 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
AR070127A1 (en) * 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
CN101531638B (en) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 Compound used as a regulator of estrogen-related receptor and applications thereof
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
ES2542835T3 (en) 2009-01-08 2015-08-12 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
JP5795304B2 (en) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション New anti-inflammatory agent
KR101892987B1 (en) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
MX2011012581A (en) * 2009-05-29 2012-01-30 Syngenta Participations Ag Substituted quinazolines as fungicides.
KR20120079111A (en) * 2009-09-24 2012-07-11 에프. 호프만-라 로슈 아게 Heterocyclic antiviral compounds
US8987301B2 (en) * 2009-11-07 2015-03-24 Merck Patent Gmbh Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors
AR079814A1 (en) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd HETEROCICLICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES
EP2539338A1 (en) * 2010-02-24 2013-01-02 Syngenta Participations AG Novel microbicides
US9073918B2 (en) 2010-05-20 2015-07-07 Takeda Pharmaceutical Company Limited Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
WO2012079079A1 (en) * 2010-12-10 2012-06-14 President And Fellows Of Harvard College Production of induced pluripotent stem cells
AR086798A1 (en) * 2011-06-29 2014-01-22 Otsuka Pharma Co Ltd USEFUL QUINAZOLINIC DERIVATIVES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP6121658B2 (en) * 2011-06-29 2017-04-26 大塚製薬株式会社 Therapeutic compounds and related methods of use
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
ES2653419T3 (en) 2013-02-01 2018-02-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN106132950B (en) 2014-01-01 2018-11-09 麦迪威森技术有限责任公司 Aminopyridines and application method
SI3321265T1 (en) 2015-03-04 2020-07-31 Gilead Sciences, Inc. 4,6-diamino-pyrido(3,2-d)pyrimidine compounds and their utilisation as modulators of toll-like receptors
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR20180032611A (en) * 2015-07-23 2018-03-30 브리스톨-마이어스 스큅 컴퍼니 TGF beta receptor antagonist
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
MA46093A (en) 2016-09-02 2021-05-19 Gilead Sciences Inc TOLL-TYPE RECEIVER MODULATING COMPOUNDS
JOP20190257A1 (en) 2017-04-28 2019-10-28 Novartis Ag 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
EP4331679A3 (en) 2017-06-21 2024-04-03 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
IL280213B2 (en) 2018-07-26 2024-06-01 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
CN109503550B (en) * 2018-11-20 2022-11-29 江西师范大学 2-azaaryl-6-substituted amino quinazolinone compound and preparation method and application thereof
WO2020113178A1 (en) * 2018-11-30 2020-06-04 Celularity, Inc. Aromatic compounds for use in activating hematopoietic stem and progenitor cells
TWI751516B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202115056A (en) 2019-06-28 2021-04-16 美商基利科學股份有限公司 Processes for preparing toll-like receptor modulator compounds
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN113620956B (en) * 2020-05-06 2023-06-13 赛诺哈勃药业（成都）有限公司 Transforming growth factor receptor antagonist, preparation method and application thereof
CN113698395B (en) * 2020-05-22 2023-12-08 赛诺哈勃药业（成都）有限公司 Transforming growth factor receptor antagonist, preparation method and application thereof
EP4284377A1 (en) * 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
US20240309015A1 (en) * 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
WO2004065392A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2004065392A8 (en) Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2005018557A3 (en) Substituted pyridinones
WO2000021926A3 (en) 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
SG179430A1 (en) Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
EA200400466A1 (en) DERIVATIVES OF PIPERAZINE WITH ANTAGONISTIC ACTIVITY TO CCR1 RECEPTOR
MXPA03000428A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives.
WO2004087677A3 (en) Pyrimidin-4-one derivatives and their use as p38 kinase modulators
ATE370138T1 (en) NEW IMIDAZOPYRIDINES AND THEIR USE
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
NO20084496L (en) Pyridyl and pyrimidinyl substituted pyrrole, thiophene and furan derivatives as kinase inhibitors
WO2007058832A3 (en) Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
MX337817B (en) PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES.
WO2002062794A3 (en) Compounds
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
WO2005037836A3 (en) Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
WO2006065590A3 (en) Pyridine and pyrimidine antiviral compositions
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
MX2010006748A (en) PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS.
WO2003087088A3 (en) (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
NO20080418L (en) Pyrido [2,3-D] pyrimidiride derivatives, process for their preparation and therapeutic use of the same
WO2007110340A3 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN GAZETTE 28/2004 UNDER (30) REPLACE "20 NOVEMBER 2002 (20.11.2002)" BY "21 NOVEMBER 2002 (21.11.2002)"

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase